Risk–benefit analysis on the clinical significance of convalescent plasma therapy in the management of COVID-19

Sivaraman Dhanasekaran,Venugopal Venkatesalu,Leela Kagithakara Vajravelu

doi:10.1136/postgradmedj-2020-138056

Abstract

The pandemic triggered by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is already on the list of the greatest threat that human beings have ever encountered in modern history....

Highlights

The pandemic triggered by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is already on the list of the greatest threat that human beings have ever encountered in modern history
Efficacy of convalescent plasma (CP) therapy measured in the scale of emerging neutralising antibody titer (NAT) level in the recipient circulation
Knowledge gaining part of this study is that quantification index on plasma collection specific for binding titer optimised as 1:1000 IgG and for neutralisation titer >40 dilution offers measurable recovery in treated cases. Another pilot study conducted in 10 cases with COVID-19 subjected to CP therapy reciprocates 100% clinical improvement with titer value >1:640, and 7 of 10 cases turn negative to viral RNA within 7 days of CP (200 mL) transfusion in addition to improved serological and radiology profile.[13]

Summary

Introduction

The pandemic triggered by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is already on the list of the greatest threat that human beings have ever encountered in modern history. Efficacy of CP therapy measured in the scale of emerging neutralising antibody titer (NAT) level in the recipient circulation.

Results

Conclusion